Osteoporosis Drugs Tied to Up to 24% Lower Dementia Risk in 120,000 Older Adults

Dementia is a growing crisis. More than 55 million people live with it worldwide, and projections reach 139 million by 2050. The first drugs that slow Alzheimer's progression have been approved, but they are costly, unsuitable for some patients, and their effectiveness is still questioned. That has pushed researchers to look for affordable, existing medications that could prevent or delay dementia before symptoms begin.

A team at the University of Hong Kong's LKS Faculty of Medicine examined electronic medical records across Hong Kong for more than 120,000 patients aged 60 and older, all with osteoporosis or fragility fractures. They compared dementia outcomes in those taking nitrogen-containing bisphosphonates (NBPs), including alendronate and zoledronate, with those who were not. NBP use was associated with up to a 24% lower risk of Alzheimer's disease and related dementias. The work was published in Alzheimer's & Dementia.

The rationale builds on a known link between bone and brain. Osteoporosis and dementia often occur in the same older adults and share risk factors, including older age, female sex and low physical activity. The same team previously showed that osteoporosis and fractures independently raise dementia risk, and that people with dementia are more likely to fall and break bones. NBPs slow bone breakdown, and some of the biological processes they influence may also play a role in Alzheimer's development.

For readers, the finding suggests that treating bone loss may carry brain benefits, and it strengthens the case for taking osteoporosis seriously as part of healthy aging. People prescribed these drugs for fracture prevention may gain an extra, though unproven, advantage.

Caveats matter. This is an observational records-based study, so it cannot establish causation. Confounding, such as differences in health, adherence or access to care, may influence results. Randomized trials are needed before NBPs are used for dementia prevention, and these drugs carry their own risks that a clinician should weigh.